Brain

Glioma

- IDH mutant astrocytoma
- IDH mutant glioma
- Recurrent glioblastoma

IDH mutant glioma

Brain metastases, not otherwise stated

Meningioma

Perihemeral Nerve Sheath Tumors

Recurrent High-Grade Radiation-Relapsed Meningioma

10067: A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients with Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy

10218: A Phase Ib Trial of CB-839 in Combination with Radiation Therapy and Temozolomide in Patients with IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma

10129: A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors (3 Cohorts: glioma, cholangiocarcinoma, other solid tumors)

9979: Phase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUDR-Mediated Tumor Radiosensitization in Brain Metastases

9952: Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of VX-970 When Combined with Whole Brain Radiotherapy (WBRT) in Patients with Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)

10042: A Phase II Trial of AZD9291 (Osimertinib) with or without Bevacizumab in Patients with EGFR Mutation Positive NSCLC and Brain Metastases

10186: A Phase I/I Study of Nivolumab Plus or Minus Ipilimumab in Combination with Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma

* 10220: A Phase II Basket Trial of Glutaminase Inhibitor (BeGiN) CB-839 HCl in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: Jan 15, 2019